|
 |
|
|
Factoid of the Day
|
Friday, May 16, 2025
|
In a breakthrough announcement, the Children's Hospital of Philadelphia reported that it had successfully treated a patient with a personalized version of CRISPR gene-editing therapy, according to The Wall Street Journal. The patient, an infant who suffers from a rare liver disease (CPS1 deficiency), received three customized CRISPR treatments between February and April of this year. In the short time since treatment began, the child has required less of his medication and has moved from the 8th percentile for weight to the 35th.
|
|
First Trust Target Outcome ETFs®
|
|
Unit Investment Trusts Upcoming Deposit Information |
Initial Offer Date |
|
Click Here
for CUSIP Information.
|
• |
Capital Strength Buy-Write, 81 |
5/16/2025 |
• |
Dow 30 Buy-Write, 15 |
5/16/2025 |
• |
S&P Dividend Aristocrats Buy-Write, 41 |
5/16/2025 |
• |
Technology Dividend Buy-Write, 27 |
5/16/2025 |
• |
Dividend Strength Opportunity, 34 |
5/19/2025 |
• |
Equity Income Select, 86 |
5/19/2025 |
• |
High-Yield Income Closed-End, 119 |
5/19/2025 |
• |
Vest Large Cap Deep Buffered 20, 81 |
5/19/2025 |
• |
Defensive Equity Buy-Write, 16 |
5/20/2025 |
• |
Energy Buy-Write, 8 |
5/20/2025 |
• |
Global Commodities Companies Buy-Write, 19 |
5/20/2025 |
• |
Key 3, 30 |
5/21/2025 |
• |
Richard Bernstein Advisors Global Dividend Kings®, 54 |
5/21/2025 |
• |
Vest Large Cap Deep Buffered 30, 39 |
5/21/2025 |
• |
WCM International Equity, 5 |
5/21/2025 |
• |
Worldwide Economic Recovery, 21 |
5/21/2025 |
• |
High Dividend Equity, 65 |
5/23/2025 |
• |
Technology Dividend, 55 |
5/23/2025 |
• |
Vest Nasdaq 100 Buffered 10, 18 |
5/23/2025 |
• |
Global Equity Income Closed-End, 93 |
5/28/2025 |
• |
Vest Enhanced Large Cap Buffered 15, 27 |
5/28/2025 |
• |
Dorsey Wright Relative Strength Dividend, 60 |
6/3/2025 |
• |
Dorsey Wright Relative Strength Top 50, 60 |
6/3/2025 |
• |
Innovative Health Care, 25 |
6/3/2025 |
• |
Precious Metals Select, 65 |
6/3/2025 |
• |
SMid Capital Strength Opportunity, 34 |
6/3/2025 |
• |
Vest Large Cap Buffered 10, 80 |
6/3/2025 |
• |
Convertible & Income Select Closed-End and ETF, 16 |
6/4/2025 |
• |
ETF Growth and Income, June 2025 |
6/4/2025 |
• |
Tactical Alpha, 46 |
6/4/2025 |
• |
American Recovery, 22 |
6/5/2025 |
• |
Banking Opportunity, 59 |
6/5/2025 |
• |
Covered Call Select Closed-End, 107 |
6/5/2025 |
• |
Vest Small Cap Buffered 20, 11 |
6/5/2025 |
• |
AI, Robotics & Technology Opportunity, 33 |
6/6/2025 |
• |
American Strength, 15 |
6/6/2025 |
• |
Dow® Target 10, June 2025 |
6/10/2025 |
• |
FT Diversified Target Income, 10 |
6/10/2025 |
• |
Global Dividend, 82 |
6/11/2025 |
• |
Health Care Select, 79 |
6/11/2025 |
• |
Market Strength Allocation Select, 62 |
6/11/2025 |
• |
Diversified High Income ETF, 5 |
6/12/2025 |
• |
FT Income, 29 |
6/12/2025 |
• |
Municipal Income ETF, 19 |
6/12/2025 |
• |
Senior Loan and Limited Duration ETF, 15 |
6/12/2025 |
• |
Capital Strength Opportunity, 38 |
6/13/2025 |
• |
International High Dividend Equity, 56 |
6/13/2025 |
• |
NextGen Communications and Technology, 27 |
6/13/2025 |
• |
Stonebridge Preferred Income, 51 |
6/13/2025 |
• |
Vest 2-Year Large Cap Buffered 20, 23 |
6/13/2025 |
• |
Vest Nasdaq 100 Buffered 20, 23 |
6/17/2025 |
|
|
|
|
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|